Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Licenses RNAi Patent to RNAx

NEW YORK, Jan. 27 (GenomeWeb News) - Alnylam Pharmaceuticals, through its German affiliate, Ribopharma, has granted a license to its RNAi patent to Ribopharma, the company said today.

 

The patent covers the use of short double-stranded RNAs for RNA interference. RNAx, based in Berlin, will pay an initial and annual licensing fees, as well as royalties on services it provides using the technology.

 

Earlier this month, Alnylam, based in Cambridge, Mass., licensed the patent to Invitrogen, Cell Signaling Technology, and Cenix Bioscience.

 

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.